Department of Pediatrics, University of Turku and Turku University Hospital, Kiinamyllynkatu 4-8, FI-20520 Turku, Finland.
J Infect. 2016 Jul 5;72 Suppl:S29-33. doi: 10.1016/j.jinf.2016.04.019. Epub 2016 May 10.
Respiratory viruses place a great disease burden especially on the youngest children in terms of high rates of infection, bacterial complications and hospitalizations. In developing countries, some viral infections are even associated with substantial mortality in children. The interaction between viruses and bacteria is probably much more common and clinically significant than previously understood. Respiratory viruses frequently initiate the cascade of events that ultimately leads to bacterial infection. Effective antiviral agents can substantially shorten the duration of the viral illness and prevent the development of bacterial complications. Viral vaccines have the potential to not only prevent the viral infection but also decrease the incidence of bacterial complications. At present, antivirals and vaccines are only available against influenza viruses, but new vaccines and antivirals against other viruses, especially for RSV, are being developed.
呼吸道病毒尤其对幼儿造成了沉重的疾病负担,其感染率高、易并发细菌感染和住院治疗。在发展中国家,一些病毒感染甚至与儿童的大量死亡相关。病毒和细菌之间的相互作用可能比以前认为的更为常见和具有临床意义。呼吸道病毒通常会引发一系列事件,最终导致细菌感染。有效的抗病毒药物可以显著缩短病毒疾病的持续时间,并预防细菌并发症的发生。病毒疫苗不仅具有预防病毒感染的潜力,而且还可以降低细菌并发症的发生率。目前,仅有针对流感病毒的抗病毒药物和疫苗,但针对其他病毒(尤其是 RSV)的新疫苗和抗病毒药物正在研发中。